Which closed-end funds own Halozyme Therapeutics Inc?
2 active closed-end funds report this security in their latest N-PORT filing, with a combined reported value of $1.1M. Security type: debt security. Country: United States. CUSIP 40637HAF6 · ISIN US40637HAF64.
Holdings are historical filings (report dates May 29, 2026 – Jul 31, 2026; N-PORT becomes public ~60 days after quarter end), not live positions. Weights are percent of each fund’s net assets. Different instruments of one issuer (shares, bonds, preferreds) are separate securities — see related securities below.
Funds holding this security
| Fund | Category | Weight | Value (USD) | Balance | Fund net assets | Prem/disc | Report date |
|---|---|---|---|---|---|---|---|
| AVK Advent Convertible & Income Fund | Convertible Securities | 0.15% | $1.1M | 743,000 par | $757M | NAV unavailable | Jul 31, 2026 |
| VGI Virtus Global Multi-Sector Income Fund | Multi-Asset | 0.01% | $11.7K | 9,000 par | $129M | 10.8% discount | May 29, 2026 |
2 positions. Source: SEC Form N-PORT via market-data vendor re-serve. Funds without an N-PORT on file cannot appear here.
Related securities from the same issuer
| Security | Type | Funds holding |
|---|---|---|
| Halozyme Therapeutics in | debt security | 10 |
| Halozyme Therapeutics Inc | common equity | 5 |
| Halozyme Therapeutics Inc | debt security | 5 |
Issuer-level search for “HALOZYME THERAPEUTICS INC” → · Compare two funds’ portfolios →